Refine
Has Fulltext
- yes (111)
Is part of the Bibliography
- yes (111)
Year of publication
Document Type
- Journal article (98)
- Doctoral Thesis (8)
- Book article / Book chapter (3)
- Report (1)
- Review (1)
Keywords
- Medizin (111) (remove)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (12)
- Neurologische Klinik und Poliklinik (12)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (9)
- Neurochirurgische Klinik und Poliklinik (9)
- Klinik und Poliklinik für Strahlentherapie (8)
- Institut für Pharmakologie und Toxikologie (5)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (5)
- Institut für Virologie und Immunbiologie (4)
- Kinderklinik und Poliklinik (4)
- Medizinische Klinik und Poliklinik II (4)
Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a serious adverse effect. Furthermore, drug cessation sometimes induces rebound disease activity of unknown etiology. Here we investigated whether binding of this adhesion-blocking antibody to T lymphocytes could modulate their phenotype by direct induction of intracellular signaling events. Primary CD4+ T lymphocytes either from healthy donors and treated with natalizumab in vitro or from MS patients receiving their very first dose of natalizumab were analyzed. Natalizumab induced a mild upregulation of IL-2, IFN-c and IL-17 expression in activated primary human CD4+ T cells propagated ex vivo from healthy donors, consistent with a pro-inflammatory costimulatory effect on lymphokine expression. Along with this, natalizumab binding triggered rapid MAPK/ERK phosphorylation. Furthermore, it decreased CD49d surface expression on effector cells within a few hours. Sustained CD49d downregulation could be attributed to integrin internalization and degradation. Importantly, also CD4+ T cells from some MS patients receiving their very first dose of natalizumab produced more IL-2, IFN-c and IL-17 already 24 h after infusion. Together these data indicate that in addition to its adhesion-blocking mode of action natalizumab possesses mild direct signaling capacities, which can support a pro-inflammatory phenotype of peripheral blood T lymphocytes. This might explain why a rebound of disease activity or IRIS is observed in some MS patients after natalizumab cessation.